MA34296B1 - Composition retard injectable antipsychotique - Google Patents
Composition retard injectable antipsychotiqueInfo
- Publication number
- MA34296B1 MA34296B1 MA35428A MA35428A MA34296B1 MA 34296 B1 MA34296 B1 MA 34296B1 MA 35428 A MA35428 A MA 35428A MA 35428 A MA35428 A MA 35428A MA 34296 B1 MA34296 B1 MA 34296B1
- Authority
- MA
- Morocco
- Prior art keywords
- composition
- biodegradable
- injectable
- retardant
- rates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION QUI PEUT ÊTRE UTILISÉE POUR ADMINISTRER UN MÉDICAMENT ANTIPSYCHOTIQUE TEL QUE LA RISPÉRIDONE SOUS FORME D'UN IMPLANT BIODÉGRADABLE DE FORMATION IN-SITU POUR LA LIBÉRATION PROLONGÉE ASSURANT DES TAUX PLASMATIQUES THÉRAPEUTIQUES DÈS LE PREMIER JOUR. LA COMPOSITION SE PRÉSENTE SOUS LA FORME D'UNE SUSPENSION MÉDICAMENTEUSE SUR UN COPOLYMÈRE OU UNE SOLUTION DE COPOLYMÈRES BIODÉGRADABLE ET BIOCOMPATIBLE UTILISANT DES SOLVANTS MISCIBLES QUI EST ADMINISTRÉE SOUS FORME LIQUIDE. UNE FOIS LA COMPOSITION EN CONTACT AVEC LES LIQUIDES CORPORELS, LA MATRICE POLYMÈRE DURCIT, RETENANT LE MÉDICAMENT, FORMANT UN IMPLANT SOLIDE OU SEMI-SOLIDE QUI LIBÈRE LE MÉDICAMENT EN CONTINU. DES TAUX PLASMATIQUES THÉRAPEUTIQUES DU MÉDICAMENT PEUVENT ÊTRE OBTENUS DÈS LE PREMIER JOUR JUSQU'AU MOINS 14 JOURS OU PLUS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382154.2A EP2394664B1 (fr) | 2010-05-31 | 2010-05-31 | Compositions pour implants biodégradables in situ injectables |
PCT/EP2011/059000 WO2011151355A1 (fr) | 2010-05-31 | 2011-05-31 | Composition retard injectable antipsychotique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34296B1 true MA34296B1 (fr) | 2013-06-01 |
Family
ID=43301889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35428A MA34296B1 (fr) | 2010-05-31 | 2011-05-31 | Composition retard injectable antipsychotique |
Country Status (32)
Country | Link |
---|---|
US (2) | US10085936B2 (fr) |
EP (2) | EP2394664B1 (fr) |
JP (1) | JP5882993B2 (fr) |
KR (1) | KR101784330B1 (fr) |
CN (1) | CN103002917B (fr) |
AP (1) | AP3524A (fr) |
AU (1) | AU2011260318B2 (fr) |
BR (1) | BR112012030686B1 (fr) |
CA (1) | CA2800111C (fr) |
CL (1) | CL2012003350A1 (fr) |
CY (2) | CY1117964T1 (fr) |
DK (2) | DK2394664T3 (fr) |
EA (1) | EA024155B1 (fr) |
ES (2) | ES2589106T3 (fr) |
HR (2) | HRP20161049T1 (fr) |
HU (2) | HUE029895T2 (fr) |
IL (1) | IL223129A (fr) |
LT (2) | LT2394664T (fr) |
MA (1) | MA34296B1 (fr) |
ME (1) | ME02501B (fr) |
MX (1) | MX338373B (fr) |
MY (1) | MY161930A (fr) |
NZ (1) | NZ604342A (fr) |
PL (2) | PL2394664T3 (fr) |
PT (2) | PT2394664T (fr) |
RS (1) | RS55190B1 (fr) |
SG (1) | SG185775A1 (fr) |
SI (2) | SI2394664T1 (fr) |
SM (2) | SMT201600320B (fr) |
UA (1) | UA108885C2 (fr) |
WO (1) | WO2011151355A1 (fr) |
ZA (1) | ZA201209346B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
NZ581862A (en) | 2007-05-25 | 2012-06-29 | Tolmar Therapeutics Inc | Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient |
EP2394663B1 (fr) | 2010-05-31 | 2021-10-13 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions pour implants biodégradables in situ injectables |
US10350159B2 (en) * | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10335366B2 (en) * | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
SI2394664T1 (sl) | 2010-05-31 | 2016-10-28 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsihotični depojski sestavek za injiciranje |
US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
PL2529757T3 (pl) * | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Formulacja implantu zawierającego paliperydon |
RS62059B1 (sr) * | 2011-05-31 | 2021-07-30 | Laboratorios Farmaceuticos Rovi S A | Kompozicija implanta risperidona i/ili paliperidona |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
BR112015022023B1 (pt) | 2013-03-11 | 2022-12-06 | Durect Corporation | Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade |
WO2016199170A2 (fr) * | 2015-06-10 | 2016-12-15 | Cipla Limited | Particules de palmitate de palipéridone et compositions à base de celles-ci |
CA3057438A1 (fr) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Formulations d'olanzapine a liberation prolongee |
CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
CN110420212A (zh) * | 2019-08-19 | 2019-11-08 | 韩自勤 | 一种用于治疗精神分裂症组合物及其制备方法 |
TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
JP3645906B2 (ja) | 1993-11-19 | 2005-05-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | マイクロカプセル封入された3−ピペリジニル−置換1,2−ベンズイソオキサゾール類及び1,2−ベンズイソチアゾール類 |
EP0949905B1 (fr) | 1996-12-20 | 2001-07-18 | Alza Corporation | Composition de gel injectable a effet retard et son procede de preparation |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6331317B1 (en) * | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
AU2001237221A1 (en) * | 2000-01-11 | 2001-07-24 | Roland Bodmeier | Implants, particles |
US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
DK1539101T3 (da) * | 2002-07-31 | 2009-04-27 | Alza Corp | Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf |
US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
JP2008518881A (ja) * | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ,エル.エル.シー. | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
ES2550014T3 (es) | 2007-02-15 | 2015-11-03 | Tolmar Therapeutics, Inc. | Poli-(lactida/glicolida) de descarga lenta y métodos para producir polímeros |
CN101677952B (zh) * | 2007-05-18 | 2012-12-05 | 杜雷科特公司 | 改进的贮库制剂 |
NZ581862A (en) * | 2007-05-25 | 2012-06-29 | Tolmar Therapeutics Inc | Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient |
WO2009060473A2 (fr) * | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Compositions injectables, procédés et utilisations correspondantes |
MX347056B (es) * | 2008-08-12 | 2017-04-10 | Novartis Ag | Composiciones farmaceuticas. |
EP2394663B1 (fr) | 2010-05-31 | 2021-10-13 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions pour implants biodégradables in situ injectables |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
SI2394664T1 (sl) | 2010-05-31 | 2016-10-28 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsihotični depojski sestavek za injiciranje |
RS62059B1 (sr) | 2011-05-31 | 2021-07-30 | Laboratorios Farmaceuticos Rovi S A | Kompozicija implanta risperidona i/ili paliperidona |
PL2529757T3 (pl) | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Formulacja implantu zawierającego paliperydon |
-
2010
- 2010-05-31 SI SI201031270A patent/SI2394664T1/sl unknown
- 2010-05-31 LT LTEP10382154.2T patent/LT2394664T/lt unknown
- 2010-05-31 ES ES10382154.2T patent/ES2589106T3/es active Active
- 2010-05-31 PL PL10382154.2T patent/PL2394664T3/pl unknown
- 2010-05-31 EP EP10382154.2A patent/EP2394664B1/fr active Active
- 2010-05-31 PT PT103821542T patent/PT2394664T/pt unknown
- 2010-05-31 HU HUE10382154A patent/HUE029895T2/en unknown
- 2010-05-31 DK DK10382154.2T patent/DK2394664T3/en active
-
2011
- 2011-05-31 SG SG2012087136A patent/SG185775A1/en unknown
- 2011-05-31 NZ NZ604342A patent/NZ604342A/en unknown
- 2011-05-31 ME MEP-2016-178A patent/ME02501B/fr unknown
- 2011-05-31 AP AP2012006626A patent/AP3524A/xx active
- 2011-05-31 MY MYPI2012701044A patent/MY161930A/en unknown
- 2011-05-31 PL PL11725383.1T patent/PL2575890T3/pl unknown
- 2011-05-31 ES ES11725383.1T patent/ES2592527T3/es active Active
- 2011-05-31 RS RS20160730A patent/RS55190B1/sr unknown
- 2011-05-31 PT PT117253831T patent/PT2575890T/pt unknown
- 2011-05-31 UA UAA201214486A patent/UA108885C2/ru unknown
- 2011-05-31 SI SI201130939A patent/SI2575890T1/sl unknown
- 2011-05-31 CA CA2800111A patent/CA2800111C/fr active Active
- 2011-05-31 LT LTEP11725383.1T patent/LT2575890T/lt unknown
- 2011-05-31 BR BR112012030686-3A patent/BR112012030686B1/pt active IP Right Grant
- 2011-05-31 EP EP11725383.1A patent/EP2575890B1/fr active Active
- 2011-05-31 DK DK11725383.1T patent/DK2575890T3/en active
- 2011-05-31 AU AU2011260318A patent/AU2011260318B2/en active Active
- 2011-05-31 MX MX2012013937A patent/MX338373B/es active IP Right Grant
- 2011-05-31 WO PCT/EP2011/059000 patent/WO2011151355A1/fr active Application Filing
- 2011-05-31 MA MA35428A patent/MA34296B1/fr unknown
- 2011-05-31 KR KR1020127033021A patent/KR101784330B1/ko active IP Right Grant
- 2011-05-31 CN CN201180026475.2A patent/CN103002917B/zh active Active
- 2011-05-31 JP JP2013512879A patent/JP5882993B2/ja active Active
- 2011-05-31 HU HUE11725383A patent/HUE029056T2/en unknown
- 2011-05-31 EA EA201201569A patent/EA024155B1/ru unknown
-
2012
- 2012-11-19 IL IL223129A patent/IL223129A/en active IP Right Grant
- 2012-11-29 CL CL2012003350A patent/CL2012003350A1/es unknown
- 2012-11-30 US US13/690,647 patent/US10085936B2/en active Active
- 2012-12-10 ZA ZA2012/09346A patent/ZA201209346B/en unknown
-
2016
- 2016-08-19 HR HRP20161049TT patent/HRP20161049T1/hr unknown
- 2016-08-29 HR HRP20161100TT patent/HRP20161100T1/hr unknown
- 2016-08-31 CY CY20161100858T patent/CY1117964T1/el unknown
- 2016-08-31 CY CY20161100857T patent/CY1117969T1/el unknown
- 2016-09-15 SM SM201600320T patent/SMT201600320B/it unknown
- 2016-09-15 SM SM201600321T patent/SMT201600321B/it unknown
-
2018
- 2018-04-04 US US15/944,894 patent/US10182982B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34296B1 (fr) | Composition retard injectable antipsychotique | |
RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
KR20180080189A (ko) | 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물 | |
MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
MY167123A (en) | Conveniently implantable sustained release drug compositions | |
BR0213143A (pt) | Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
JP2008513506A5 (fr) | ||
MA44206B1 (fr) | Comprimé orodispersible comprenant estetrol | |
NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
FR19C1030I1 (fr) | Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles | |
JP2015531373A5 (fr) | ||
MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
TW200815410A (en) | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | |
Thomsen et al. | Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats | |
MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
BRPI0513222A (pt) | agente para promoção de recuperação de disfunção após o inicio de doença neurológica central | |
PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
RU2552290C1 (ru) | Соединения опиоидных антагонистов и их применение при лечении склеродермии | |
TW200501946A (en) | Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight |